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Sumoylation regulates lamin A function
and is lost in lamin A mutants associated
with familial cardiomyopathies
Yu-Qian Zhang and Kevin D. Sarge

THE JOURNAL OF CELL BIOLOGY

Department of Molecular and Cellular Biochemistry, Chandler Medical Center, University of Kentucky, Lexington, KY 40536

L

amin A mutations cause many diseases, including
cardiomyopathies and Progeria Syndrome. The covalent attachment of small ubiquitin-like modiﬁer
(SUMO) polypeptides regulates the function of many proteins. Until now, no examples of human disease-causing
mutations that occur within a sumoylation consensus sequence and alter sumoylation were known. We show that
lamin A is sumoylated at lysine 201 and that two lamin A
mutants associated with familial dilated cardiomyopathy,
E203G and E203K, exhibit decreased sumoylation. E203

occupies the conserved +2 position in the sumoylation
consensus ⌿KXE. Lamin A mutants E203G, E203K, and
K201R all exhibit a similar aberrant subcellular localization and are associated with increased cell death. Fibroblasts from an individual with the E203K lamin A mutation
also exhibit decreased lamin A sumoylation and increased
cell death. These results suggest that SUMO modiﬁcation
is important for normal lamin A function and implicate an
involvement for altered sumoylation in the E203G/E203K
lamin A cardiomyopathies.

Introduction
The lamin A protein plays an important role in the structure and
function of the nucleus, and mutations in the lamin A gene cause
a large number of different human diseases, including cardiomyopathies, muscular dystrophies, and Hutchinson-Gilford
Progeria Syndrome (Broers et al., 2006; Capell and Collins,
2006; Mattout et al., 2006; Parnaik and Manju, 2006). Covalent
attachment of small ubiquitin-like modifier (SUMO) proteins to
lysine residues in target proteins, or sumoylation, is an important regulator of protein functional properties (Hay, 2005;
Bossis and Melchior, 2006; Kerscher et al., 2006). SUMO proteins are covalently attached to target lysine residues by the
SUMO E2 enzyme ubc9, and these substrate lysines are typically found within the consensus sequence ⌿KXE (⌿ represents
hydrophobic amino acids; Desterro et al., 1997; Johnson and
Blobel, 1997; Rodriguez et al., 2001; Sampson et al., 2001).
Cells express three major SUMO paralogues, SUMO-1, SUMO-2,
and SUMO-3, with SUMO-2 and -3 being much more similar to
each other than to SUMO-1 (Hay, 2005; Kerscher et al., 2006;
Bossis and Melchior, 2006).
Using a yeast two-hybrid screen, a previous study identified an interaction between lamin A and ubc9, the SUMO E2
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protein (Zhong et al., 2005). Based on this interaction, we hypothesized that the lamin A protein could be a target of sumoylation. The purpose of the experiments in this present study
was to determine whether lamin A is indeed sumoylated in cells
and, if so, what role this modification plays in regulating the
function of this lamin.

Results and discussion
First, we sought to test for sumoylation of endogenous lamin A
by performing immunoprecipitation of HeLa cell extracts using
lamin A antibodies, followed by Western using antibodies against
SUMO-1 or SUMO-2/SUMO-3 (because of the similarity of
SUMO-2 and -3, it is likely that both of these SUMO proteins
are recognized by this antibody). The results suggest that lamin A
is SUMO modified and that it is preferentially modified by
SUMO-2 compared with SUMO-1 (Fig. 1 A). The results in
Fig. 1 C indicate that lamin A protein in extracts of mouse heart
is also sumoylated and that, like lamin A that is present in HeLa
cell extracts, SUMO-2 appears to be the predominant SUMO
protein attached to this protein.
Analysis of the lamin A amino acid sequence revealed a
match to the sumoylation consensus sequence ⌿KXE (MKEE)
surrounding lysine 201 in the rod-containing domain of lamin A
(Fig. 2 A, top). To test whether sumoylation of the lamin A is
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Figure 1. Endogenous lamin A is sumoylated.
(A) Extracts of HeLa cells were subjected to
immunoprecipitation using anti–lamin A antibodies followed by Western blot assays using
antibodies against SUMO-2, SUMO-1, or lamin A (different from those used for immunoprecipitation). (B) Western blot assays of HeLa
cell lysates used for the immunoprecipitations
using anti–SUMO-2 or –SUMO-1 antibodies.
(C) Extracts prepared from mouse heart were
subjected to immunoprecipitation using anti–
lamin A antibodies followed by Western blot
assays using antibodies against SUMO-2,
SUMO-1, or lamin A (different from those used
for immunoprecipitation).

occurring at lysine 201, HeLa cells were transfected with mammalian expression plasmids encoding GFP fusion constructs of
wild-type lamin A and lamin A in which this lysine was changed
to a nonsumoylatable arginine (K201R), along with expression
constructs encoding HA-tagged SUMO-1 or -2. Extracts of the
transfected cells were subjected to immunoprecipitation with
anti-GFP antibodies followed by anti-HA Western blot. The results of this experiment, in agreement with the results obtained
for endogenous lamin A, indicated that the wild-type lamin A
protein is covalently modified by SUMO-2 but not as efficiently
sumoylated by SUMO-1 (Fig. 2 A, bottom). The results also
show that the modification by SUMO-2 is not observed for the
K201R lamin A mutant protein, suggesting that lysine 201 is the
site of SUMO-2 attachment in this protein.
The glutamic acid residue at the fourth position in the sumoylation consensus sequence ⌿KXE is known to be important
for the efficiency of SUMO addition to the nearby lysine in this
sequence (Rodriguez et al., 2001; Sampson et al., 2001). Relevant to this, two different disease-associated mutations of the
human lamin A gene have been identified that change the glutamic acid at this position (E203) in the sumoylation consensus
sequence of this protein to a different amino acid (Fig. 2 B, top;
Fatkin et al., 1999; Jakobs et al., 2001). In one of these mutants,
glutamic acid 203 is changed to glycine (E203G), whereas in
the other, it is changed to lysine (E203K). Both the E203G and
E203K mutations of lamin A are associated with familial dilated
cardiomyopathy and conduction system disease (Fatkin et al.,
1999; Jakobs et al., 2001), but the underlying molecular mechanism by which these mutations alter lamin A function is not
known. Based on the results in the previous paragraph demonstrating that sumoylation of the lamin A protein occurs at lysine
201 and on previous results indicating the importance of glutamic acid for sumoylation at the preceding lysine of the ⌿KXE
sumoylation consensus sequence (Rodriguez et al., 2001; Sampson
et al., 2001), we hypothesized that the E203G and E203K mutations could possibly mediate their deleterious effects by resulting in decreased sumoylation of the lamin A protein. To test the
feasibility of this hypothesis, we performed a transfection immunoprecipitation experiment similar to that shown in Fig. 2 A, except that here the sumoylation of wild-type GFP–lamin A was
compared with that of GFP–lamin A constructs containing the
E203G or E203K mutations. The results of this experiment,
shown in Fig. 2 B (bottom), indicate that both the E203G and
36
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E203K mutant lamin A proteins exhibit decreased sumoylation
compared with the wild-type lamin A protein.
Sumoylation plays an important role in regulating the
functional properties of target proteins in cells (Hay, 2005; Bossis
and Melchior, 2006; Kerscher et al., 2006). The wild-type
lamin A protein exhibits a characteristic pattern of localization
at the nuclear periphery (Broers et al., 2006; Capell and Collins,
2006; Mattout et al., 2006; Parnaik and Manju, 2006). We hypothesized that sumoylation of lamin A at lysine 201 may be
important for this localization pattern. To test this hypothesis,
HeLa cells were transfected with the wild-type or K201R lamin A GFP fusion expression plasmids and then examined by
fluorescence microscopy. As shown in Fig. 3 A, the wild-type
lamin A GFP fusion protein exhibits the typical pattern of relatively continuous nuclear peripheral localization. However, the
K201R lamin A GFP fusion protein shows an altered localization
pattern, with the mutant protein appearing to concentrate into
foci. These results suggest that sumoylation of lamin A is important for the normal pattern of subcellular localization of this
protein. Analysis of the subcellular localization of GFP fusion
constructs of the E203G or E203K mutant lamin A proteins
by fluorescence microscopy reveals that both of these mutant
proteins exhibit altered localization patterns similar to that of
the K201R mutant lamin A, in which these proteins are concentrated in foci, in contrast to the more continuous appearance
of the wild-type lamin A at the nuclear periphery (Fig. 3 A).
The pattern we observed for the E203G lamin A is similar to
that observed by a previous study (Lloyd et al., 2002). To our
knowledge, the localization of the E203K lamin A has not
previously been reported. The percentages of cells exhibiting
abnormal localization of the wild-type and mutant GFP–lamin A
proteins are shown in Table S1 (available at http://www.jcb.org/
cgi/content/full/jcb.200712124/DC1).
To confirm the effects of altered localization of the cardiomyopathy-associated E203G and E203K lamin A mutants in a
more physiologically relevant cell type, we repeated the experiments shown in Fig. 3 A in mouse embryonic cardiomyocytes.
The results, shown in Fig. 3 B, indicate that the K201R, E203G,
and E203K lamin A mutants all exhibit aberrant localization patterns in the cardiomyocytes (compared with wild-type lamin A)
that are similar to those observed in HeLa cells. Percentages of
cells exhibiting abnormal localization of wild-type and mutant
GFP–lamin A are shown in Table S1.

In light of the defective sumoylation and aberrant localization patterns of the K201R, E203G, and E203K lamin A mutant
proteins, we hypothesized that expression of these lamin A mutant proteins could result in decreased cell viability. The results
shown in Fig. 3 C indicate that this appears to be the case, as all
three of these mutant lamin A proteins are associated with increased cell death.
In the final set of experiments, we examined skin fibroblasts obtained from a patient that is heterozygous for the E203K
lamin A mutation, which, as already described, is associated
with cardiomyopathy (Jakobs et al., 2001). Immunoprecipitation of lamin A from these cells followed by SUMO-2 Western
blot indicates that, as expected, levels of sumoylation of lamin A
are reduced in cells from this individual compared with cells of
a normal individual (Fig. 4 A). This individual is heterozygous
for the E203K lamin A mutation, thus we expect that lamin A
sumoylation was decreased but not eliminated. Further, immunofluorescence analysis of lamin A indicated more cells showing
abnormal lamin A localization and nuclear morphology for the
E203K fibroblasts compared with normal fibroblasts (Fig. 4 B).
The percentages of normal and E203K fibroblasts exhibiting
abnormal lamin A localization/nuclear morphology are shown
in Table S1. The E203K fibroblasts also exhibit increased cell
death compared with the control fibroblasts (Fig. 4 C).
The results presented in this paper indicate that lysine 201
of lamin A is a target of covalent modification by the SUMO-2
protein and that this sumoylation is important for the normal
pattern of subcellular localization of the lamin A protein. The results of these experiments also show that lamin A sumoylation is
decreased in transfected mutant E203G and E203K lamin A proteins that cause familial dilated cardiomyopathies and in lamin A
of fibroblasts of individuals with the E203K mutation. To our
knowledge these are the first examples of human disease-causing
mutations occurring in a crucial residue of a sumoylation consensus sequence and resulting in decreased sumoylation of the
mutant protein.
The results also indicate that the mutant E203G and E203K
lamin A proteins exhibit altered subcellular localization patterns
that are very similar to that of the SUMO attachment site mutant
K201R lamin A protein. These results suggest a role for sumoylation in the correct localization of lamin A in the cell. Further, cells transfected with the E203G and E203K lamin A
proteins and skin fibroblasts of individuals with the E203K mutation exhibit higher levels of cell death compared with cells transfected with wild-type lamin A or normal skin fibroblasts,
respectively. Together, these results suggest that sumoylation is
important for normal lamin A function and support a role for altered sumoylation in the underlying molecular mechanism of
familial dilated cardiomyopathies associated with the E203G/
E203K lamin A mutations.

Figure 2. Lamin A is sumoylated at lysine 201 by SUMO-2, and E203G
and E203K mutant lamin A proteins exhibit decreased sumoylation. (A) The
top shows the location of a match (MKEE) to the sumoylation site consensus
sequence (⌿KXE) surrounding lysine 201 in the rod-containing domain of
lamin A. In the bottom, extracts of HeLa cells transfected with GFP fusion
constructs of wild-type lamin A or K201R mutant lamin A and HA-tagged
SUMO-1 or -2 plasmids were subjected to immunoprecipitation using antiGFP antibodies followed by anti-HA Western blot. Western blots of the
lysates using anti-GFP and anti-HA antibodies show levels of GFP–lamin A
proteins and HA–SUMO-1/HA–SUMO-2 proteins (incorporated into major
sumoylated proteins), respectively. (B) The top shows the location of the
E203G and E203K mutations in lamin A associated with familial dilated
cardiomyopathy at the conserved glutamic acid residue of the sumoylation
site consensus sequence (⌿KXE) surrounding lysine 201. In the bottom,
extracts of HeLa cells transfected with GFP fusion constructs of wild-type
lamin A, E203G mutant lamin A, or E203K mutant lamin A along with
HA-tagged SUMO-2 were subjected to immunoprecipitation with anti-GFP
antibodies followed by anti-HA Western blot. Levels of transfected GFP–
lamin A proteins in the cell lysates were determined by Western blot using
anti-GFP antibody.

Materials and methods
Cell culture and plasmids
HeLa cells were cultured in DME medium (Mediatech, Inc.) supplemented
with 10% FBS and 100× antibiotic-antimycotic (Invitrogen) in 5% CO2.
Human skin ﬁbroblasts (provided by R. Hershberger, University of Miami,
Miami, FL) were cultured in the same media supplemented with 2 mM

glutamine. Transfection of HeLa cells was performed using Effectene transfection reagent (QIAGEN), according to the manufacturer’s protocol. Immunoprecipitation analysis and ﬂuorescence microscopy were performed 48 h
after the transfection. The GFP–lamin A plasmid was constructed from the
pcDNA3.1-LMNA plasmid (gift of N. Zhong and W.T. Brown, Institute for
Basic Research in Developmental Disabilities, Staten Island, NY). The coding
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Figure 3. SUMO site K201R mutant lamin A and cardiomyopathy-associated E203G and E203K mutant lamin A proteins exhibit similar patterns of aberrant localization. (A and B) Wild-type, K201R, E203G, and E203K lamin A GFP fusion expression plasmids were transfected into HeLa cells (A) or mouse
embryonic cardiomyocytes (B), and the subcellular localization of the GFP–lamin A proteins was examined by confocal ﬂuorescence microscopy. DNA
was visualized by staining with HOECHST 33342. Bars, 5 μm. (C) Wild-type, K201R, E203G, or E203K lamin A GFP fusion expression plasmids were
transfected into HeLa cells, which were then analyzed by trypan blue assay to measure cell death. Data are shown as means ± SEM. (*, P < 0.0001; **,
P < 0.0002; ***, P < 0.0001 [for lamin A mutants vs. wild type]) and are each from three datasets.
region of the lamin A protein was cut out with EcoRI and BamHI digestion and ligated into pEGFP-C2 vector (Clontech Laboratories, Inc.).
Mutagenesis PCR was performed to generate GFP–lamin A K201R,
E203G, and E203K mutants. The primers used for the mutagenesis were
as follows (only top primers are listed, bottom primers are the reverse complements of each of these): K201R, 5⬘-CTG CAG ACC ATG AGG GAG
GAA CTG GAC-3⬘; E203G, 5⬘-ACC ATG AAG GAG GGA CTG GAC
TTC CAG-3⬘; and E203K, 5⬘-ACC ATG AAG GAG AAA CTG GAC TTC
CAG-3⬘. HA–SUMO-1 and –SUMO-2 were expressed using pcDNA3–
HA–SUMO-1 and –HA–SUMO-2 plasmids (provided by K. Orth, University of Texas Southwestern, Dallas, TX).
Immunoprecipitation analysis
For immunoprecipitation experiments, the cell pellets of the transfected
HeLa cells or the human skin fibroblasts were resuspended in 500 μl
RIPA buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.4, 1% NP-40, 0.2%
SDS, 0.25% sodium deoxycholate, and 1 mM EDTA) with protease inhibitor cocktail (Roche), 1 mM DTT, and 20 mM N-ethylmaleimide
(added fresh). Cell lysis was performed by sonication, after which the
sample was incubated on ice for 20 min. After centrifugation at 10,000 rpm
at 4°C for 10 min, the supernatant was transferred to a fresh tube, and
20 μl of the whole cell lysate was removed for analysis of the level of
transfected GFP–lamin A. 300 μl of 50% protein G–Sepharose slurry
(GE Healthcare) was washed three times with PBS and resuspended in
RIPA buffer to make a 50% slurry. The cell lysate was precleared by
mixing it with 150 μl of this slurry and 5 μg of goat IgG and incubating
at 4°C for 60 min. After centrifugation at 4,000 rpm at 4°C for 1 min,
the supernatant was transferred to a fresh tube and mixed with 5 μg of
anti-GFP antibody (Bethyl Laboratories, Inc.) or anti–lamin A antibody
(BD Biosciences). After incubation at 4°C for 60 min, 150 μl of 50%
protein G–Sepharose slurry was added and incubated at 4°C for 60 min.
The beads were washed with RIPA buffer four times and then boiled in
50 μl of 4× SDS-PAGE loading buffer. After brief centrifugation, the supernatants were subjected to SDS-PAGE and Western blot using the antibodies
described in the next section.
Western blot analysis and antibodies
SDS-PAGE and Western blot were performed according to standard procedures. The antibodies and dilutions used to probe the Western blots were
as follows. Goat anti-GFP antibody (Bethyl Laboratories, Inc.) was used at
1:2,000, mouse anti-HA antibody (gift from D. Andres laboratory, Univer-
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sity of Kentucky, Lexington, KY) was used at 1:2,000, goat anti–SUMO-1
antibody (Bethyl Laboratories, Inc.) was used at 1:1,000, rabbit anti–
SUMO-2 antibody (Abgent) was used at 1:500, and rabbit anti–lamin A
antibody (Abcam) was used at 1:500.
Fluorescence and immunoﬂuorescence microscopy
Cells were seeded on coverslips. At 48 h after transfection with the wildtype or point mutant GFP–lamin A expression constructs, HOECHST 33342
and verapamil were added to the medium to ﬁnal concentrations of 5 and
50 μg/ml, respectively. After incubation at 37°C for 30 min, the coverslips were washed twice with PBS and then incubated in 3.7% PFA at
room temperature for 20 min. After two washes with PBS and a wash with
distilled water, the coverslips were wicked on a kimwipe to partially dry
and then mounted onto a slide spotted with 15 μl of VectorShield (Vector
Laboratories). For immunostaining, after two washes with PBS, the coverslips were incubated in PBS containing 3% BSA at 37°C for 1 h and then
incubated with rabbit anti–lamin A antibody (1:1,000) at 37°C for 30 min.
After the coverslip was washed twice with PBS, it was incubated with Fluorescein anti–rabbit IgG (1:200) at 37°C for 30 min. After two washes
with PBS and a brief wash with distilled water, the coverslip was mounted
onto a slide spotted with 15 μl of VectorShield. Excess ﬂuid was wicked
from the coverslips, and the edges of the coverslip were sealed with ﬁngernail polish. The ﬂuorescence was then visualized using a confocal (TCS
SP5; Leica) or ﬂuorescent (Nikon) microscope with a Spotcam digitalimaging camera (Nikon). Figures were made from the images using Photoshop (Adobe).
Trypan blue cell viability assay
Cells were collected by centrifugation at 1,000 rpm for 10 min at 4°C, and
the pellet was washed twice with PBS. The cell pellet was then resuspended
in PBS to a concentration of ⵑ106 cells/ml. A one to one dilution of the
suspension was prepared using a solution containing 0.4% trypan blue
stain (Invitrogen), and the suspension was then loaded into the counting
chamber of a hemacytometer. The number of stained cells, as well as the
total number of cells, was counted, and the percentage of stained cells was
taken to represent the percentage of cell death. Three datasets were analyzed for each experiment.
Statistical analysis
Statistical signiﬁcance was determined using Student’s t test. A p-value of
<0.05 was considered to be statistically signiﬁcant.

Online supplemental material
Table S1 contains quantitation analysis for the experiments in Fig. 3 (A and B)
and Fig. 4 B. This table shows the percentages of HeLa cells or cardiomyocytes transfected with GFP lamin A wild-type, K201R, E203G, or E203K
mutants that exhibit abnormal lamin A localization and the percentages of
normal versus E203K lamin A ﬁbroblasts showing abnormal lamin A localization/nuclear morphology. Online supplemental material is available at
http://www.jcb.org/cgi/content/full/jcb.200712124/DC1.
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individual heterozygous for the E203K lamin A mutation were subjected
to immunoﬂuorescence analysis using anti–lamin A antibodies. DNA was
visualized by staining with HOECHST 33342. Bar, 5 μm. (C) Skin ﬁbroblasts of a normal individual and E203K lamin A individual were analyzed
by trypan blue assay to measure cell death. Data are shown as means ±
SEM (P < 0.0038 for E203K lamin A mutant cells vs. wild-type cells) and
are from three datasets.
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